Clinical Trials Logo

Thyroid Cancer clinical trials

View clinical trials related to Thyroid Cancer.

Filter by:

NCT ID: NCT05446441 Not yet recruiting - Thyroid Cancer Clinical Trials

Endoscopic Thyroidectomy Versus Open Thyroidectomy for Papillary Thyroid Carcinoma

Start date: June 28, 2022
Phase: N/A
Study type: Interventional

Recently, endoscopic thyroidectomy using gasless unilateral transaxillary approach has been proven feasible and safe in several Chinese medical centers. This study is aimed to compare multi-institutional Chinese outcomes of endoscopic thyroidectomy using gasless unilateral transaxillary approach and conventional open surgery.

NCT ID: NCT05428371 Not yet recruiting - Thyroid Cancer Clinical Trials

Assessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features

THYOMICS
Start date: January 1, 2023
Phase:
Study type: Observational

Indeterminate thyroid nodules have a mild risk of malignancy (15-30%). The aim of our study is to individuate new biomarkers of thyroid carcinoma through multiomic analyses of blood samples and of specimen samples of patients with indeterminate thyroid nodules.

NCT ID: NCT05323669 Not yet recruiting - Thyroid Cancer Clinical Trials

Molecular Profile of Thyroid Nodules

MPTN
Start date: April 11, 2022
Phase:
Study type: Observational

Profiling and comparative analysis of genomic alterations and miRNA expression in benign and malignant thyroid tumors using histological and cytological specimens will be performed. Obtained information is necessary to create a molecular test to refine the cancer risk of cytologically indeterminate thyroid nodules.

NCT ID: NCT05275374 Not yet recruiting - Cancer Clinical Trials

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

ENHANCE
Start date: December 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF V600 mutation. This study is divided into three stages: Phase Ia: a dose-escalation phase of XP-102; Phase Ib: a dose-escalation and sample size expansion phase of XP-102 plus trametinib; Phase IIa: an expansion phase of XP-102 plus trametinib.

NCT ID: NCT05265819 Not yet recruiting - Thyroid Cancer Clinical Trials

Effect of Exergaming Exercises and Mediterranean Diet on Thyroid Cancer Patients Following Total Thyroidectomy

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Effect of exergaming exercises and mediteranean diet on thyroid cancer patients following total thyroidectomy adult patients from both gender will be randomly assigned equally to exergaming exercises, Mediterranean diet groups using computer-generated block randomization. Group A: Control group No intervention was provided for 12 weeks except thyroid hormone replacement therapy Group B: Exergaming exercise The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed three times a week, for a total of 12 weeks Group C: Mediterranean diet All participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.PREDIMED questionnaire is used To assess adherence to the Mediterranean diet Group D: Exergaming exercises and Mediterranean diet Exergaming exercises are used in addition to Mediterranean diet

NCT ID: NCT05252884 Not yet recruiting - Thyroid Cancer Clinical Trials

Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial

Start date: March 30, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to compare the frequency of post-thyroidectomy symptomatic and biochemical hypocalcaemia between the strategy of routine prophylactic calcium + calcitriol vs the administration of calcium guided by PTH values.

NCT ID: NCT05124938 Not yet recruiting - Thyroid Cancer Clinical Trials

Assessment of CA 19-9 in Patients' With Thyroid Malignancies

Start date: December 1, 2021
Phase:
Study type: Observational

Thyroid cancer is a rare disease that represents approximately 3.8% of all new cancer cases.Incidence of thyroid cancer in north Africa about 2.8% of all new cancer cases with mortality rate about 0.73%.Thyroid malignancies are classified into different groups as follows:Papillary thyroid cancer which is the most common form of thyroid cancer form about 80-90% of all thyroid cancers,Follicular thyroid cancer that forms about 10-15% of all thyroid cancers,Anaplastic thyroid cancer that forms less than 2% of all thyroid cancers,Medullary thyroid cancer that forms about 5-10% and other rare types include thyroid lymphoma, and thyroid sarcoma. Medullary thyroid carcinoma (MTC) is a rare disease, and its classic tumor marker is calcitonin. However, recently, very aggressive cases have been reported to also secrete carbohydrate antigen 19-9 (CA19-9), and its role as a marker of worse prognosis has been questioned.

NCT ID: NCT04612894 Not yet recruiting - Thyroid Cancer Clinical Trials

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.

NCT ID: NCT04560426 Not yet recruiting - Thyroid Cancer Clinical Trials

Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation

Start date: October 31, 2020
Phase: N/A
Study type: Interventional

This intraoperative parathyroid gland auxiliary recognition system uses the principle of parathyroid gland autofluorescence to assist surgeons in accurately identifying and protecting parathyroid glands during surgery, reducing the possibility of postoperative hypoparathyroidism. This study will explore the protective effect of the parathyroid gland auxiliary recognition instrument on parathyroid function during thyroid malignant tumor surgery through reasonable grouping.

NCT ID: NCT04524884 Not yet recruiting - Thyroid Cancer Clinical Trials

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of the combination of Toripalimab and Surufatinib for Locally Advanced Thyroid Cancer.